1) Why was the dose of 0.2 mcg/kg of background vasopressors considered high dose when in clinical practice initial dose can be as high as 10-12 mcg/kg of Levophed and maintenance dose of upto 4 mcg/kg
2) Why was the study not powered to statistically detect mortality benefit as other vasopressors also raise MAP but not necesarrily have mortality benefit? What makes Ag II any different?
3) Where does the Ag II drug stand currently with FDA approval?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.